KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Long-Term Debt Repayments (2018 - 2025)

NovoCure's Long-Term Debt Repayments history spans 8 years, with the latest figure at $560.9 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $560.9 million; the TTM value through Dec 2025 reached $560.9 million, up 4244.03%, while the annual FY2025 figure was $560.9 million, 4244.03% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $560.9 million at NovoCure, up from $12.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $560.9 million in Q4 2025 and bottomed at $3000.0 in Q2 2023.
  • The 5-year median for Long-Term Debt Repayments is $7000.0 (2021), against an average of $47.8 million.
  • The largest annual shift saw Long-Term Debt Repayments crashed 100.0% in 2021 before it soared 430333.33% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $7000.0 in 2021, then changed by 0.0% to $7000.0 in 2022, then plummeted by 57.14% to $3000.0 in 2023, then skyrocketed by 430333.33% to $12.9 million in 2024, then surged by 4244.03% to $560.9 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Long-Term Debt Repayments are $560.9 million (Q4 2025), $12.9 million (Q2 2024), and $3000.0 (Q2 2023).